PeptideScanner retained ClinicalTrials.gov record NCT05326776 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT06677502 at 2026-11-16T17:33:14.861Z. Its registry update date was 2024-12-31, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04775953 at 2026-11-15T22:01:45.056Z. Its registry update date was 2024-12-10, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01950403 at 2026-07-30T18:37:14.701Z. Its registry update date was 2024-12-09, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02685397 at 2026-07-30T18:37:14.689Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04966741 at 2026-07-30T18:38:25.516Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT03035032 at 2026-07-30T18:38:25.519Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03965130 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-26, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02366494 at 2026-07-30T18:38:25.510Z. Its registry update date was 2024-11-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04883346 at 2026-07-30T18:38:25.517Z. Its registry update date was 2024-11-20, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04943068 at 2026-07-30T18:38:25.522Z. Its registry update date was 2024-11-13, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT05804162 at 2026-07-30T18:38:25.523Z. Its registry update date was 2024-11-01, and PeptideScanner's reviewed identity mapping was cagrilintide.
PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02975999 at 2026-11-15T22:08:31.832Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT06519656 at 2026-07-30T18:39:33.787Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was mazdutide.
PeptideScanner retained ClinicalTrials.gov record NCT03471728 at 2026-07-30T18:39:33.779Z. Its registry update date was 2024-10-18, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT05709444 at 2026-07-30T18:39:33.780Z. Its registry update date was 2024-10-17, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT02310269 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT03839823 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT04460560 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-10-09, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT01794793 at 2026-11-15T22:05:38.400Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT05181800 at 2026-11-15T21:52:09.579Z. Its registry update date was 2024-09-27, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03935984 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00702520 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT06581679 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-09-03, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06099067 at 2026-07-30T18:41:37.931Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT03036800 at 2026-07-30T18:41:37.923Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04179734 at 2026-07-30T18:41:37.916Z. Its registry update date was 2024-08-09, and PeptideScanner's reviewed identity mapping was bremelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT06208540 at 2026-11-16T17:33:14.861Z. Its registry update date was 2024-08-05, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT02403284 at 2026-07-30T18:42:56.623Z. Its registry update date was 2024-07-22, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03891875 at 2026-07-30T18:42:56.626Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT06498063 at 2026-07-30T18:42:56.616Z. Its registry update date was 2024-07-12, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT05151328 at 2026-07-30T18:42:56.581Z. Its registry update date was 2024-07-11, and PeptideScanner's reviewed identity mapping was plecanatide.
PeptideScanner retained ClinicalTrials.gov record NCT02400801 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-07-10, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05242783 at 2026-11-15T21:47:40.408Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT06473259 at 2026-11-15T21:49:16.513Z. Its registry update date was 2024-06-25, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT05849389 at 2026-07-30T18:43:56.187Z. Its registry update date was 2024-06-24, and PeptideScanner's reviewed identity mapping was vosoritide.
PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT04249232 at 2026-07-30T18:43:56.172Z. Its registry update date was 2024-06-14, and PeptideScanner's reviewed identity mapping was abaloparatide.
PeptideScanner retained ClinicalTrials.gov record NCT02927392 at 2026-07-30T18:43:56.185Z. Its registry update date was 2024-06-13, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03812991 at 2026-11-15T21:54:02.201Z. Its registry update date was 2024-06-11, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT01194271 at 2026-07-30T18:43:56.180Z. Its registry update date was 2024-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00089895 at 2026-11-15T21:59:29.646Z. Its registry update date was 2024-05-17, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT05027308 at 2026-11-15T21:55:23.600Z. Its registry update date was 2024-05-16, and PeptideScanner's reviewed identity mapping was teduglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT05046132 at 2026-07-30T18:45:10.886Z. Its registry update date was 2024-05-03, and PeptideScanner's reviewed identity mapping was setmelanotide.
PeptideScanner retained ClinicalTrials.gov record NCT04028765 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-30, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT04522622 at 2026-07-30T18:46:20.407Z. Its registry update date was 2024-04-23, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT03098797 at 2026-07-30T18:46:20.414Z. Its registry update date was 2024-04-16, and PeptideScanner's reviewed identity mapping was elamipretide.
PeptideScanner retained ClinicalTrials.gov record NCT04279314 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-11, and PeptideScanner's reviewed identity mapping was trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT04181723 at 2026-11-15T21:57:22.404Z. Its registry update date was 2024-04-08, and PeptideScanner's reviewed identity mapping was trofinetide.
PeptideScanner retained ClinicalTrials.gov record NCT02918864 at 2026-11-16T00:59:19.138Z. Its registry update date was 2024-04-05, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03007979 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-20, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT04103034 at 2026-11-16T01:33:21.554Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT04767802 at 2026-11-16T01:38:51.796Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was rusfertide.
PeptideScanner retained ClinicalTrials.gov record NCT06303284 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-18, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00295646 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-15, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT02278120 at 2026-11-15T21:50:32.222Z. Its registry update date was 2024-03-12, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT02953665 at 2026-07-30T18:47:17.465Z. Its registry update date was 2024-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03672812 at 2026-07-30T18:47:17.466Z. Its registry update date was 2024-03-05, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02636270 at 2026-11-16T17:35:13.282Z. Its registry update date was 2024-02-28, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT03149445 at 2026-11-16T17:29:46.323Z. Its registry update date was 2024-02-26, and PeptideScanner's reviewed identity mapping was tesofensine.
PeptideScanner retained ClinicalTrials.gov record NCT00947531 at 2026-11-16T17:33:14.861Z. Its registry update date was 2024-02-21, and PeptideScanner's reviewed identity mapping was cerebrolysin.
PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide.
PeptideScanner retained ClinicalTrials.gov record NCT00099086 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02543255 at 2026-07-30T18:49:14.746Z. Its registry update date was 2024-01-31, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT03617536 at 2026-11-15T21:56:33.343Z. Its registry update date was 2024-01-24, and PeptideScanner's reviewed identity mapping was difelikefalin.
PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide.